ストックスクリーナーアプリを入手
3.10
9.09%
-0.31
アフターアワーズ：
3.12
0.02
+0.65%
前日終値:
$3.41
開ける：
$3.4
24時間の取引高:
643.17K
Relative Volume:
1.11
時価総額：
$271.05M
収益：
$33.98M
当期純損益:
$-95.10M
株価収益率:
-0.3098
EPS:
-10.0072
ネットキャッシュフロー:
$-106.13M
1週間 パフォーマンス:
-16.44%
1か月 パフォーマンス:
-16.22%
6か月 パフォーマンス:
+8.77%
1年 パフォーマンス:
-79.68%
1日の値動き範囲:
$3.09
$3.415
1週間の範囲:
$3.09
$3.7799
52週間の値動き範囲:
$1.35
$16.29
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.10 | 298.16M | 33.98M | -95.10M | -106.13M | -10.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is X4 Pharmaceuticals Inc. forming a bullish divergenceWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - TMX Newsfile
How X4 Pharmaceuticals Inc. stock trades before earnings2025 Growth vs Value & Detailed Earnings Play Strategies - mfd.ru
Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsTrade Volume Summary & Accurate Buy Signal Notifications - mfd.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
Layoff Tracker: Ultragenyx Downsizes By 10% After Bone Drug’s Phase 3 Fail - BioSpace
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - stocktitan.net
Insider Returns Down To US$57k As X4 Pharmaceuticals' Stock Dips 11% - simplywall.st
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
X4 Pharmaceuticals: Commercial Execution Takes Center Stage - AD HOC NEWS
Aug Gainers: Can X4 Pharmaceuticals Inc sustain earnings growthWall Street Watch & Entry Point Confirmation Alerts - baoquankhu1.vn
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Top Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price - simplywall.st
What is the fair value of X4 Pharmaceuticals Inc. stock nowMarket Sentiment Report & Community Consensus Picks - mfd.ru
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
Pfizer Inc. - Britannica
Prescription Drug Costs - Britannica
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 - Yahoo Finance
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages - Defense World
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Moving Averages: How much upside does X4 Pharmaceuticals Inc have2025 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
More Than 30,000 Prescribed Cholesterol Drugs Recalled Nationwide - The Healthy @Reader's Digest
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
Exit Recap: Is X4 Pharmaceuticals Inc stock a value trapWeekly Stock Recap & AI Driven Stock Movement Reports - baoquankhu1.vn
Budget pitch: Pharma Inc seeks tax breaks for research and development - The Economic Times
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Jennison Associates LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug Breakouts: What is the long term forecast for X4 Pharmaceuticals Inc stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Lilly, Takeda targeted by legal strategy usually reserved for the mob - Pharma Voice
Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
4.46%
大文字化:
|
ボリューム (24 時間):